Does Rallies show Form 4 insider transactions for TXG?

Yes. Rallies tracks TXG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TXG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TXG. It does not provide personalized investment advice.

TXG (10x Genomics, Inc. Class A Common Stock) Stock Analysis - Insider Trades

10x Genomics, Inc. Class A Common Stock (TXG) is a publicly traded Healthcare sector company. As of May 21, 2026, TXG trades at $23.98 with a market cap of $2.72B and a P/E ratio of -137.82. TXG moved +7.58% today. Year to date, TXG is +30.90%; over the trailing twelve months it is +164.10%. Its 52-week range spans $6.78 to $26.45. Analyst consensus is buy with an average price target of $24.10. Rallies surfaces TXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TXG stock inside the company?

Recent TXG insider activity includes Saxonov Serge sold 5.00K, Saxonov Serge sold 5.00K, Saxonov Serge sold 10.00K, Saxonov Serge sold 14.29K, and Saxonov Serge sold 1.86K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TXG Key Metrics

Key financial metrics for TXG
Metric	Value
Price	$23.98
Market Cap	$2.72B
P/E Ratio	-137.82
EPS	$-0.17
Dividend Yield	0.00%
52-Week High	$26.45
52-Week Low	$6.78
Volume	0
Avg Volume	0
Revenue (TTM)	$638.78M
Net Income	$-22.66M
Gross Margin	69.60%

Recent TXG Insider Trades

Saxonov Serge sold 5.00K (~$122.78K) on Apr 14, 2026.
Saxonov Serge sold 5.00K (~$97.61K) on Mar 24, 2026.
Saxonov Serge sold 10.00K (~$191.30K) on Mar 23, 2026.
Saxonov Serge sold 14.29K (~$323.99K) on Mar 2, 2026.
Saxonov Serge sold 1.86K (~$43.11K) on Mar 2, 2026.

Latest TXG News

10x Genomics Sees Q1 Revenue of $150.8M, Launches Atera Platform — May 7, 2026
10x Genomics Debuts Atera Platform for Whole-Transcriptome Spatial Analysis — Apr 19, 2026
PerturbAI and 10x Genomics Unveil 8 Million-Cell In Vivo CRISPR Atlas — Mar 17, 2026
10x Genomics Q4 Beats Estimates, Narrows Loss to $0.13; Shares Jump 10.5% — Feb 13, 2026
10x Genomics to Analyze 1,000 Autoimmune Cases, Establish CLIA Lab and Launch 20,000-Sample AI Oncology Project — Jan 12, 2026

TXG Analyst Consensus

12 analysts cover TXG: 0 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.10.

Common questions about TXG

Who is trading TXG stock inside the company?: Recent TXG insider activity includes Saxonov Serge sold 5.00K, Saxonov Serge sold 5.00K, Saxonov Serge sold 10.00K, Saxonov Serge sold 14.29K, and Saxonov Serge sold 1.86K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TXG?: Yes. Rallies tracks TXG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TXG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TXG. It does not provide personalized investment advice.